周一盘中，诺瓦瓦克斯医药（NVAX）股价大跌5.02%，引发市场关注。这一跌势与美国食品药品监督管理局（FDA）一位具有争议的官员重返职位的消息密切相关。
据报道，此前被解职的FDA疫苗监管官员Vinay Prasad将重新执掌FDA生物制品评价与研究中心。Prasad曾因多项决定引发争议，其中包括限制诺瓦瓦克斯医药和Moderna新冠疫苗的使用范围。这一人事变动引发了生物科技板块的普遍下跌，多家公司股价在盘前交易中出现大幅下挫。
分析人士认为，Prasad的回归可能意味着FDA对生物制品、特别是疫苗的监管态度将更趋严格。这一前景引发了投资者对诺瓦瓦克斯医药等疫苗生产商未来业务发展的担忧，从而导致其股价下跌。投资者将密切关注FDA后续的政策动向及其对生物科技行业的潜在影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.